At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 75 enrolled
Drug / intervention
Nasal Glucagon (NG) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Center, Randomized, Parallel Safety Study To Evaluate The Immunogenicity Of A Novel Glucagon Formulation Compared To Commercially Available Glucagon Administered By Intramuscular Injection In Adults With Type 1 OR Type 2 Diabetes
In Brief
A Phase 3 clinical trial evaluating Nasal Glucagon (NG) and Glucagon IM for Drug-specific Antibodies and Diabetes Mellitus. Completed, enrolled 75 participants across 1 site.
Detailed Summary
This study provides information on immunogenicity of Nasal Glucagon (AMG504-1) with regards to the potential development of treatment-emergent anti-glucagon antibodies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDrug-specific Antibodies, Diabetes Mellitus
CountriesCanada
CollaboratorsLocemia Solutions ULC
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartSep 2013
First PostedOct 2013
Primary CompletionDec 2013
TodayJul 2026
First PostedOct 10, 2013
Enrollment StartSep 1, 2013
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 12.7 years ago
Interventions
Nasal Glucagon (NG)drug
Glucagon IMdrug